Keywords: aFVII; activated FVII; AHA; acquired hemophilia A; anti-hFVIII; anti-human FVIII; aPCC; activated prothrombin complex concentrate; aPTT; activated partial thromboplastin time; AT; antithrombin; AUC; area under the curve; BPA; bypassing agent; BU; Bethesda
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: formulation; pharmacokinetics; liposomes; proteins; pharmacodynamics; rhGAA; recombinant human acid α-glucosidase; PI; phosphatidylinositol; FVIII; factor VIII; GAA; acid α-glucosidase; 4-MUG; 4-methylumbelliferyl-α-d-glucopyranoside; PI-rhGAA; PI lipo
Keywords: VTE; venous thromboembolism; HSCT; hematopoietic stem cell transplant; LMWH; low molecular weight heparin; IMIDs; immunomodulatory drugs; AML; acute myeloid leukemia; IQR; interquartile range; TAT; thrombin antithrombin; FVII; factor VII; FVIII; factor VI
Keywords: phospholipids; liposomes; apoptosis; immune response; proteins; biotechnology; HA; Hemophilia A; FVIII; factor VIII; GAA; acid alpha glucosidase; rhGAA; recombinant human GAA; PS; phosphatidylserine; TIM-4; T-cell immunoglobulin and mucin 4; MOG; myelin o
Keywords: BAC; blood alcohol concentration; BSA; bovine serum albumin; CD; cluster of differentiation; CFT; clot formation time; CT; clotting time; EDTA; ethylenediaminetetraacetic acid; FBS; fetal bovine serum; FVIII; coagulation factor VIII; FVIII:C; FVIII activi
Keywords: Early intervention (education); Hemophilia; Illness behavior; Pain; Quality of life; Rehabilitation; FVIII; factor VIII; FIX; factor IX; IBQ; Illness Behavior Questionnaire; RMAV; repeated-measures analysis of variance; VAS; visual analog scale;
Keywords: thromboembolic event; hypercoagulable state; blood clot; A2AP; α2-antiplasmin; ACTH; Adrenocorticotropic hormone; ATIII; Antithrombin III; BMI; Body mass index; CRH; Corticotropin-releasing hormone; DVT; Deep-vein thrombosis; FVIII; Factor VIII; NIH; Na
Keywords: aPCC; activated prothrombin complex concentrate; aPL; antiphospholipid; FIX; factor IX; FMD; flow-mediated dilatation; FV; factor V; FVIII; factor VIII; HA; hemophilia A; HB; hemophilia B; HIV; human immunodeficiency virus; IMT; intima-media thickness; MT
Keywords: MELD; Model for End-stage Liver Disease; vWF-Ag; von Willebrand factor antigen; PC; protein C; AT; antithrombin; FVIII; factor VIII; PH; portal hypertension; VB; variceal bleeding; AUC; area under the curve; von Willebrand factor antigen; Procoagulant imb
Keywords: APC; antigen-presenting cells; BcR; B cell receptor; EMA; European Medicines Agency; Fc; crystallizable fragment; FcγR; receptor for IgG Fc portion; FcRn; neonatal Fc receptor; FVIIa; activated factor VII; FVIII; factor VIII; GLP-1; glucagon-like peptide
Keywords: aPTT; Activated partial thromboplastin time; α2M-Thrombin; Alpha2 macroglobulin-thrombin; Anti-FXa; Anti-factor X activated; CAT; Calibrated automated thrombography; DVT; Deep venous thromboembolism; ETP; Endogenous thrombin potential; FVIII; Factor VI
Keywords: CLD; chronic liver disease; CP; Child Pugh; PT-INR; prothrombin time-international normalized ratio; VTE; venous thromboembolism; RR; relative risk; ETP; endogenous thrombin potential; PC; protein C; FVIII; factor VIII; BCS; Budd-Chiari syndrome; NC-PVT;
Keywords: ADP; adenosine diphosphate; AE2; anion exchanger 2; Ala; alanine; AMP; adenosine monophosphate; AP; alkaline phosphatase; Arg; arginine; ATP; adenosine triphosphate; ASGP-R; asialoglycoprotein receptor; Asn; asparagine; ASOR; asialoorosomucoid; BDL; bile
Pleiotropic effects of n-6 and n-3 fatty acid-related genetic variants on circulating hemostatic variables
Keywords: AA; African American; aPTT; activated partial thromboplastin time; ARIC; the Atherosclerosis Risk in Communities Study; CHS; the Cardiovascular Health Study; DHA; docosahexaenoic acid; DPA; docosapentaenoic acid; EA; European ancestry; EPA; eicosapentaeno
Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse model
Keywords: FVIII; Factor VIII; PS; phosphatidylserine; HA; Hemophilia A; Tregs; regulatory T cells; Lyso-PS; Lyso-phosphatidylserine; DMPC; dimyrisotylphosphatidylcholine; OVA; ovalbumin; GFP; green fluorescent protein; SC; subcutaneous; IV; intravenous; APC; antige
HIF1-alpha Regulates Acinar Cell Function and Response to Injury in Mouse Pancreas
Keywords: Mouse Model; Fibrinogen; Blood Clotting; Factor VIII; AP; acute pancreatitis; Fib-γD; fibrinogen-γ dimers; FVIII; factor VIII; HIF1α; hypoxia-inducible factor-1α; TF; tissue factor; VEGF; vascular endothelial growth factor;
The factor VIII heavy chain improves emicizumab-tenase assembly to enhance the factor VIII-mimicking cofactor activity
Keywords: Intrinsic tenase; FIXa; FX; FVIII; Bispecific antibody;
Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy
Keywords: BCR; B-cell receptor; CAR; chimeric antigen receptor; FVIII; factor VIII; HLA; human leukocyte antigen; ITI; immune tolerance induction; ITAMs; immunoreceptor tyrosine-based activation motifs; MHC; major histocompatibility complex; MBP; myelin basic pro
Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors
Keywords: Haemophilia A; FVIII; Inhibitors; Autoantibodies; India
Hunting down factor VIII in the immunopeptidome
Keywords: FVIII; Hemophilia A; Mass spectrometry; Inhibitors; Peptide presentation;
Current view and outcome of ITI therapy - A change over time?
Keywords: aPCC; activated prothrombin complex concentrate; d; day; BU; Bethesda units; ED; exposure days; EHTSB; European Haemophilia Therapy Strategy Board; FVIII; factor eight; FIX; factor nine; HA; haemophilia A; HB; haemophilia B; IS; immunosuppression; I-ITI;
Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model
Keywords: protein delivery; lipids; phosphatidylserine; immunology; immune tolerance; BMDCs; bone marrow derived dendritic cells; FVIII; factor VIII; HA; hemophilia A; Nabs; anti-FVIII neutralizing antibodies; PS; phosphatidylserine;
Free thiol groups in von Willebrand factor (VWF) are required for its full function under physiological flow conditions
Keywords: ADAMTS-13; a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; DTT; dithiothreitol; ECM; extracellular matrix; ELISA; enzyme linked immunosorbent assay; FVIII; coagulation factor VIII; GOF; gain-of-function; GPIb; glycoprote
Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
Keywords: FVIII; factor VIII; rFVIIIFc; recombinant human factor VIII Fc; BDD; B-domain deleted; FL-rFVIII; full length recombinant factor VIII; Treg; regulatory T-cells; TNF-α; tumor necrosis factor-α; IFN-γ; Interferon-γ; Hemophilia A; Immune tolerance; Regul
ADAMTS13 content and VWF multimer and triplet structure in commercially available VWF/FVIII concentrates
Keywords: Wilate®; ADAMTS13; VWF triplets; von Willebrand factor; VWF/FVIII concentrate; ADAMTS13; A Disintegrin And Metalloproteinase with a ThromboSpondin type 1 motif, member 13; Act; activity; Ag; antigen; BW; body weight; FRET; fluorescence resonance energy t
Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study
Keywords: AHA; Acquired haemophilia A; APTT; activated partial thromboplastin time; rFVIIa; recombinant activated factor VII; aPCC; activated prothrombin complex concentrate; PCC; prothrombin complex concentrate; TG; thrombin generation; FVIII; factor VIII; DDAVP;
Treatment of minor severe acquired haemophilia. Is there a rationale for immunoadsorption?
Keywords: Acquired haemophilia; FVIII; Immune Tolerance Induction MBMP protocol; Immunomodulation; Immunoadsorption; APTT
Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion
Keywords: TF; tissue factor; sTF; soluble tissue factor; FVIIa; factor VIIa; FVIII; factor VIII, FIX, factor IX; FX; factor X; Recombinant FVIIa; rFVIIa; Bypass therapy; Prophylaxis; Hemophilia;
Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein
Keywords: rFVIIIFc; Human cell line; HEK 293H; Hemophilia A; Manufacturing; Recombinant; aPTT; activated partial thromboplastin time; α-Gal; galactose-α-1,3-galactose; BDD; B domain-deleted; FcRn; neonatal Fc receptor; FVIII; factor VIII; HC; heavy chain; HCP; ho
Comparison of automated von Willebrand factor activity assays
Keywords: CCC; Concordance coefficient of correlation; CI; Confidence interval; CV; Coefficient of variation; FVIII; coagulation factor VIII; GPIbα; glycoprotein Ibα; LOD; Limit of detection; PB; Passing Bablok; rGPIbα; recombinant glycoprotein Ibα; VWD; Von Wi
Distribution, genetic and cardiovascular determinants of FVIII:c - Data from the population-based Gutenberg Health Study
Keywords: CAD; history of coronary artery disease; CHF; history of chronic heart failure; COPD; chronic obstructive pulmonary disease; CRP; C-reactive protein; CVD; history of cardiovascular disease; CVRF; cardiovascular risk factor; FVIII; coagulation factor VIII;
Regular ArticleA comprehensive study of ovine haemostasis to assess suitability to model human coagulation
Keywords: PLT; platelet count; PT; prothrombin time; aPTT; activated partial thrombin time; TCT; thrombin clotting time; Fib(C); fibrinogen (clauss); vWF; von Willebrand factor; FVIII; factor VIII; FXII; factor XII; Pl.Inh; plasmin inhibitor; Prot.C; protein C; AT;
D-dimer, FVIII and thrombotic burden in the acute phase of deep vein thrombosis in relation to the risk of post-thrombotic syndrome
Keywords: D-dimer; FVIII; Thrombotic score; Deep vein thrombosis; Post-thrombotic syndrome; Residual venous obstruction;
Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE®), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: A multicentre, retrospective study
Keywords: AE; Adverse event; BU; Bethesda units; CR; Complete response; CVAD; Central venous access device; F; Failed ITI; FEIBA; FVIII inhibitor bypassing activity; FVIII; Factor VIII; HTC; Haemophilia treatment centre; I-ITI; International Immune Tolerance study;
Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A - an Israeli-German multicenter database study
Keywords: BU; Bethesda units; ED; exposure days; F2; Factor 2 rs1799963; F5; Factor 5 rs6025; FVIII; Factor VIII; F8; Factor 8 genotypes; HA; hemophilia A; HRI; high-titer inhibitor; HR/CI; hazard ratio/confidence interval; ICH; intracranial hemorrhage; IFS; inhibi
Functional characterization of a novel missense mutation, His147Arg, in A1 domain of FV protein causing type II deficiency
Keywords: FV; Congenital factor V; FVIII; coagulation FVIII; FX; coagulation factor X; MD; molecular dynamics; CP; ceruloplasmin; wt; wild-type; Asp; aspartic acid; His; histidine; Arg; arginine; Cys; cystein; PCR; polymerase chain reaction; PDB; protein data bank;
Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor
Keywords: AUC; area under the curve; Cl; clearance; DAB; 3,3â²-diaminobenzidine; dIF; double immunofluorescence; EGFR; epidermal growth factor receptor; GAG; glycosaminoglycans; GPI; glycosylphosphatidylinositol; FVIII; Factor VIII; FIX; Factor IX; FXa; Factor Xa;
Evaluation and performance characteristics of the Q Hemostasis Analyzer, an automated coagulation analyzer
Keywords: aPTT; activated partial thromboplastin time; AT; antithrombin; CV; coefficient of variation; FV; (coagulation) factor V; FVIII; (coagulation) factor VIII; INR; international normalized ratio; ISI; international sensitivity index; MNPT; mean normal prothro
Overexpression of factor VII ameliorates bleeding diathesis of factor VIII-deficient mice with inhibitors
Keywords: FVII; Factor VII; FVIII; Factor VIII; AAV; adeno-associated virus; F8KO; Factor VIII knock out; HCR; hepatic control region; HAAT; human alpha-1 antitrypsin; CMV; cytomegalovirus; SV40; simian virus 40; PCR; polymerase chain reaction; PT; prothrombin time
Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII
Keywords: α-Gal; Galα1-3Galβ1-GlcNAc-R; Asn/N; asparagine; BHK; baby hamster kidney; CHO; Chinese hamster ovary; EIC; extracted ion chromatogram; FVIII; factor VIII; HA; Haemophilia A; HEK; human embryonic kidney; HexNAcHexNAc; hexosamine-hexosamine; HPAEC-PAD;
ReviewT-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Keywords: Td; T-cell dependent, thymus dependent; T; thymus; ADA; anti-drug antibodies; Ti; T-cell independent; APC; antigen-presenting cells; HLA; human leukocyte antigen; MHC; major histocompatibility complex; TCR; T cell receptor; Treg; regulatory T cells; FVIII
Long term outcome of patients with acquired haemophilia – A monocentre interim analysis of 82 patients
Keywords: Acquired haemophilia; FVIII; Immune tolerance induction MBMP protocol; Immunmodulation; Immunoadsorption; APTT
Hypercoagulability Markers Predict Thrombosis in Single Ventricle Neonates Undergoing Cardiac Surgery
Keywords: 21; ATIII; antithrombin III; CI; confidence interval; CPB; cardiopulmonary bypass; FVIII; factor VIII; ICU; intensive care unit; LOS; length of stay; PAI-1; plasminogen activator inhibitor; PC; protein C; PPP; platelet poor plasma; PS; protein S; RFU; rel
The Mesenchymal Stem Cells Derived from Transgenic Mice Carrying Human Coagulation Factor VIII Can Correct Phenotype in Hemophilia A Mice
Keywords: Hemophilia A; MSCs; FVIII; Transgenic mouse; Gene therapy
Challenges in the laboratory analyses of bleeding disorders
Keywords: aPTT; activated partial thromboplastin time; CAT; calibrated automated thrombography; ETP; endogenous thrombin potential; EQA; external quality assurance; FVIII; factor VIII; FIX; factor IX; FVIII:C; coagulation activity of FVIII; FIX:C; coagulation activ
Persistent high factor VIII activity leading to increased thrombin generation - A prospective cohort study
Keywords: D-dimer; Factor VIII; FVIII; pathophysiology; thrombin generation; venous thrombosis;
Global haemostasis assays, from bench to bedside
Keywords: α; angle that assesses rate of clot formation; α2M; α2-macroglobulin; AMC; 7-amino-4-methylcoumarine; AT; antithrombin; AUC; area under the curve; APC; activated protein C; aPTT; activated partial thromboplastin time; A10; the amplitude after ten minut
Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma
Keywords: GBM; glioblastoma; PI3K; phosphatidylinositol-3-kinase; mTOR; mammalian target of rapamycin; MRI; magnetic resonance imaging; CT; computerized axial tomography; FDG-PET; [18F] 2-fluoro-2-deoxy-D-glucose positron emission tomography; MRS; magnetic resonanc
Comparability studies of new 3rd generation recombinant human factor VIII GreenGene F after improvement of formulation and viral inactivation/removal process
Keywords: B-Domain deleted recombinant factor VIII; GreenGene F; Homogeneous FVIII; Comparability; Viral inactivation; Protein characteristics; FVIII; human factor VIII; rFVIII; recombinant FVIII; S/D; solvent/detergent; BDD-rFVIII; B-domain deleted recombinant fac
Laboratory identification of factor inhibitors: an update
Keywords: APTT; Bethesda assay; Factor inhibitors; lupus inhibitor; mixing tests; replacement therapy; APTT; activated partial thromboplastin time; aVWS; acquired von Willebrand syndrome; DIC; disseminated intravascular coagulation; dRVVT; dilute Russell's viper